title: [Chemotherapy for CRPC].
abstract: Cabazitaxel, new chemotherapeutic agent for castration resistant prostate cancer (CRPC) treated after docetaxel, was developed. In addition, new hormonal drugs for CRPC, such as enzalutamide and abiraterone were also approved in Japan recently. Treatment strategy for CRPC using these drugs is still controversial, therefore we need much more clinical data of Japanese patients with CRPC. Management of this severe condition and future of prostate cancer were discussed.
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Ozono
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furuse
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen